Evaluating Adenoma Recurrence After Endoscopic Mucosal Resection With Margin Marking or Post Treatment With Snare Tip Soft Coagulation
Launched by ADVENTHEALTH · Jun 24, 2024
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how often adenomas, which are non-cancerous growths in the colon, come back after a procedure called endoscopic mucosal resection (EMR). The trial is comparing two different techniques: one that marks the edges of the tissue being removed (EMR-MM) and another that uses heat to treat the edges after removal (EMR-STSC). The goal is to find out if these two methods lead to similar rates of adenoma recurrence.
If you are 18 years or older and scheduled for a colonoscopy to have a non-pedunculated polyp (a type of growth that isn’t on a stalk) that is 20 mm or larger removed, you might be eligible to participate in this study. Participants will undergo one of the two EMR techniques during their colonoscopy. It’s important to know that certain conditions, like having smaller polyps, inflammatory bowel disease, or being pregnant, may exclude someone from joining the trial. This study is currently recruiting participants, and it aims to help improve treatment options for colon polyps.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 years or older
- • 2. Ability to provide informed consent
- • 3. Patient scheduled to undergo colonoscopy for the evaluation and removal of colon polyps
- • 4. Non-pedunculated polyps ≥ 20 mm size
- Exclusion Criteria:
- • 1. Pedunculated polyps
- • 2. Inflammatory bowel disease
- • 3. Inability to provide informed consent
- • 4. Lesions \< 20 mm in size (largest dimension)
- • 5. Lesion involves the lips of the ileocecal valve, is located at the appendiceal orifice and/or is fully circumferential.
- • 6. Any standard contraindication, including pregnancy, to anesthesia and/or colonoscopy
About Adventhealth
AdventHealth is a comprehensive, faith-based healthcare organization dedicated to providing holistic care and advancing medical research through innovative clinical trials. With a commitment to improving patient outcomes and enhancing the quality of life, AdventHealth integrates cutting-edge technology and compassionate care across its extensive network of hospitals and outpatient facilities. The organization emphasizes a patient-centered approach, fostering collaboration among multidisciplinary teams to explore new treatment options and therapies. By participating in clinical research, AdventHealth aims to contribute to the advancement of medical knowledge and deliver transformative healthcare solutions to communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orlando, Florida, United States
Patients applied
Trial Officials
Dennis Yang, MD
Principal Investigator
AdventHealth
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported